We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.

September 4, 2020

News You Need - 3 Big Little Things from HealthXL

Announcements/News
Laura Loughrey
&

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines? We’ve included three industry experts who can help you get behind these stories - just let us know if you’d like us to make the introduction!

It's a sign! ''Telavongo''

Story snapshot:
There is not one person we have all spoken to over the last 2 days who has not been talking about it. The Teladoc-Livongo mega merger is unmissable. Is this the sign that will move skeptics over to believers [in the promise of telehealth]? Are we on track to creating the largest virtual clinic of all time?

Why is it notable? 

Industry Implications 

Glen Tullman
Glen Tullman
Executive Chairman
Livongo

Glen recently spoke at our event HealthXL Interactive on the merger, and what this means for the future of care delivery.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Uber Health and Prescription Delivery

Story snapshot: Uber Health has partnered with NimbleRx to enable prescription delivery in Dallas and Seattle.

Why is it notable? 

Industry Implications -Patient data and market monopolization concerns need to be averted

John Brownstein
John Brownstein
Chief Innovation Officer
Boston Children's Hospital

John launched Circulation, a service to offer Uber and Lyft as non-emergency medical transportation.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ro, Ro, Ro into telehealth

Story snapshot: In three years, Ro has managed to hit a reported $1.5 billion valuation for its transformation from a company focused on treating erectile dysfunction to a telemedicine service for a range of elective and urgent care-focused treatments.

Why is it notable? 

Evolving offerings of a very new company: Through Rory for women’s health, Roman for men’s health and Zero for smoking cessation, Ro now treats 20 conditions, including sexual health, weight loss, dermatology, allergies. They have gone from selling erectile dysfunction medication and hair loss supplements to becoming a telehealth company with three online health clinics (with a desire to expand into remote monitoring for chronic conditions)

Ro is D2C, and we as an industry wonder who pays in healthcare but they have demonstrated that in some cases, patients are willing to pay for their own benefit. 

Industry Implications 

Many billions: Not only is Ro valued at >$1 bil, its competitor, Hims is also looking to go public at the $1 billion mark. So, sometimes I wonder if all the conversations we are having on realistically making money from telehealth is an illusion. There is certainly a disconnect - do these valuations mean these companies are making money, have established ROI and robust business models?

Spread too thin: Lately, a lot of companies seem to be venturing into every possible arm of telehealth/virtual care. Will this dilute the quality and experience they are able to offer to patients, clinicians and others? Traditional wisdom would suggest focusing and delivering on one very clear value proposition.


Timothy Aungst
Timothy Aungst
Associate Professor of Pharmacy Practice
MCPHS University

Timothy is a pharmacist and teacher, and is passionate about all things that can enhance the delivery of care to patients.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Ready to read more? HealthXL members can access the full peak of the report on the HealthXL Community Hub.

Not yet a member of HealthXL? Download your 11 page snapshot of the report.

Download your 11 page snapshot

Connect with peers and share insights

Don't miss out on the discussion of the latest insights and reports on digital health. Meet with peers and take a deep dive for 75 minutes. Unlike at webinars, you can freely exchange experiences and insights to solve challenges and design the future of DTx.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

The Power of Real-World Evidence in DTx-Pharma partnerships

3rd March @ 11:00 am EDT

Join our Digital Health Meeting as we discuss the power of RWE in DTx-Pharma partnerships. This is a great opportunity to connect with new people and listen to valuable insights from thought leaders in the industry. Apply promptly to avoid missing out.

Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx- Overview of the market and deals

8th March @ 10.30am EDT

Join our Digital Health Meeting as we discuss the DTx market and also the most remarkable investments and partnerships in the DTx industry in recent times. Listen, engage and enjoy.

Featuring
Dr Uzma Choudry
Dr Uzma Choudry
Venture Capital Investor, Octopus Ventures
Elan Tye
Elan Tye
Principal, JAZZ Venture Partners
Featuring
Dr Uzma Choudry
Dr Uzma Choudry
Venture Capital Investor, Octopus Ventures
Elan Tye
Elan Tye
Principal, JAZZ Venture Partners
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

How should we measure efficacy and safety of DTx products?

15th March @ 11:00am EDT

Join us as we discuss how efficacy and safety should be measured in DTx products. Apply now to interact with your peers and gain insight from thought leaders in the industry.

Featuring
Jessica Shull
Jessica Shull
European Lead, Digital Therapeutics Alliance
Jin Lee
Jin Lee
Director of Digital Health Product, Astellas
Featuring
Jessica Shull
Jessica Shull
European Lead, Digital Therapeutics Alliance
Jin Lee
Jin Lee
Director of Digital Health Product, Astellas
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

Making sense of DTx partnerships

16th March @ 10:00am EDT

Join our Digital Health Meeting as we discuss making sense of DTx partnerships. Apply promptly to secure your place and connect with new people.

Featuring
Joris van Dam
Joris van Dam
Head of Digital Therapeutics, Novartis
Vijesh Unnikrishnan
Vijesh Unnikrishnan
Associate Principal, ZS
Featuring
Joris van Dam
Joris van Dam
Head of Digital Therapeutics, Novartis
Vijesh Unnikrishnan
Vijesh Unnikrishnan
Associate Principal, ZS

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

HealthXL Digital Health Meetings

Want to join the discussion now?

Join our Digital Health Meetings and take a deep dive for 75 minutes into topics like digital therapeutics, patient support, telehealth, clinical trials, dermatology and many more. These Meetings are not regular webinars: No audience, no recording and no hiding behind a screen. You actively participate in a discussion to solve your present challenges and design the future of digital health. And with a free account on our Community Hub, you stay connected and up-to-date on the latest news and insights, allowing you to fully immerse yourself in the topic before, during and after.

Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

The Power of Real-World Evidence in DTx-Pharma partnerships

3rd March @ 11:00 am EDT

Join our Digital Health Meeting as we discuss the power of RWE in DTx-Pharma partnerships. This is a great opportunity to connect with new people and listen to valuable insights from thought leaders in the industry. Apply promptly to avoid missing out.

Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Featuring
Aahuti Rai
Aahuti Rai
Chief Strategy & Growth Officer at Ampersand Health
Philip Russmeyer
Philip Russmeyer
Founder & CEO, FITFILE
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

DTx- Overview of the market and deals

8th March @ 10.30am EDT

Join our Digital Health Meeting as we discuss the DTx market and also the most remarkable investments and partnerships in the DTx industry in recent times. Listen, engage and enjoy.

Featuring
Dr Uzma Choudry
Dr Uzma Choudry
Venture Capital Investor, Octopus Ventures
Elan Tye
Elan Tye
Principal, JAZZ Venture Partners
Featuring
Dr Uzma Choudry
Dr Uzma Choudry
Venture Capital Investor, Octopus Ventures
Elan Tye
Elan Tye
Principal, JAZZ Venture Partners
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation
Clinical Trials Innovation

Trial design to validate a digital health product

9th March @ 11:30am EDT

Join our Digital Health Meeting focused on the topic of Trial design to validate a digital health product. Apply now to get involved in the discussion, gain valuable insights and make new connections.

Featuring
Francesca Wuttke
Francesca Wuttke
Chief Digital Officer, Almirall
Quentin Le Masne
Quentin Le Masne
Director, Connected Health & Devices at Merck Group
Featuring
Francesca Wuttke
Francesca Wuttke
Chief Digital Officer, Almirall
Quentin Le Masne
Quentin Le Masne
Director, Connected Health & Devices at Merck Group
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)
Digital Therapeutics (DTX)

How should we measure efficacy and safety of DTx products?

15th March @ 11:00am EDT

Join us as we discuss how efficacy and safety should be measured in DTx products. Apply now to interact with your peers and gain insight from thought leaders in the industry.

Featuring
Jessica Shull
Jessica Shull
European Lead, Digital Therapeutics Alliance
Jin Lee
Jin Lee
Director of Digital Health Product, Astellas
Featuring
Jessica Shull
Jessica Shull
European Lead, Digital Therapeutics Alliance
Jin Lee
Jin Lee
Director of Digital Health Product, Astellas

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

We cannot guarantee that the content will display correctly while using Internet Explorer. To have the best browsing experience, please upgrade to Microsoft Edge, Google Chrome or Safari.